Image

Post Market Clinical Follow-up (PMCF) Study of the A.L.P.S. Proximal Humerus Plating System

Post Market Clinical Follow-up (PMCF) Study of the A.L.P.S. Proximal Humerus Plating System

Not Recruiting
18 years and older
All
Phase N/A

Powered by AI

Overview

This study is a multicenter, prospective, non-randomized, non-controlled post-market clinical follow-up study. The primary objective of this study is to confirm the safety and performance of the A.L.P.S. Proximal Humerus Plating System applied in proximal humerus fracture treatment.

Description

The A.L.P.S. Proximal Humerus Plating System was developed to provide another surgical option for proximal humerus fracture fixation. The aim of the A.L.P.S. Proximal Humerus Plating System is to provide increased fracture stability while simultaneously increasing range of motion and decreasing the likelihood of screw perforation.

A minimum of 7 and maximum of 10 sites globally will be involved in this study. This number of clinical sites will allow for a better generalization of study data as well as allow for consistency to be developed across multiple regions. 135 implants will be included into the study. Each site will be allowed to enroll 27 humeri. Enrollment is competitive. All potential study subjects will be required to participate in the Informed Consent process.

Eligibility

Inclusion Criteria:

  • Patient must be 18 years of age or older.
  • Patient must have a primary proximal humerus fracture (Orthopaedic Trauma Association/ American Orthopedic 11-A, B, C) requiring surgical intervention and be eligible for fixation by plate and screws.
  • Patients with failed conservative treatment within 3 weeks since injury.
  • Patient must be able and willing to complete the protocol required follow-up.
  • Patient must have a signed Institutional Review Board/Ethics Committee approved informed consent.
  • Patient must be in a good nutritional state

Exclusion Criteria:

  • Delay of surgery for more than 3 weeks.
  • Tumor induced fractures
  • Patient is a prisoner.
  • Pregnancy/ breast feeding
  • Patient is a current alcohol or drug abuser.
  • Patient has a mental or neurologic condition that will not allow for proper informed consent and/or participation in follow-up program.
  • Patient has an active infection.
  • Patient conditions including limitations in blood supply, obesity, or insufficient quantity or quality of bone stock.
  • Patient is sensitive to foreign body material.

Study details
    Osteoarthritis
    Rheumatoid Arthritis
    Post-Traumatic Arthritis
    Psoriatic Arthritis
    Proximal Humeral Fracture

NCT03626038

Zimmer Biomet

28 November 2025

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.